| Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes Y Qie, H Yuan, CA Von Roemeling, Y Chen, X Liu, KD Shih, JA Knight, ... Scientific reports 6 (1), 26269, 2016 | 310 | 2016 |
| Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma CA Von Roemeling, LA Marlow, JJ Wei, SJ Cooper, TR Caulfield, K Wu, ... Clinical Cancer Research 19 (9), 2368-2380, 2013 | 280 | 2013 |
| Pathway signature and cellular differentiation in clear cell renal cell carcinoma HW Tun, LA Marlow, CA von Roemeling, SJ Cooper, P Kreinest, K Wu, ... PloS one 5 (5), e10696, 2010 | 211 | 2010 |
| Pathway analysis of primary central nervous system lymphoma HW Tun, D Personett, KA Baskerville, DM Menke, KA Jaeckle, P Kreinest, ... Blood, The Journal of the American Society of Hematology 111 (6), 3200-3210, 2008 | 190 | 2008 |
| Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4 CA Von Roemeling, DC Radisky, LA Marlow, SJ Cooper, SK Grebe, ... Cancer research 74 (17), 4796-4810, 2014 | 173 | 2014 |
| A novel γ-secretase assay based on detection of the putative C-terminal fragment-γ of amyloid β protein precursor I Pinnix, U Musunuru, H Tun, A Sridharan, T Golde, C Eckman, ... Journal of Biological Chemistry 276 (1), 481-487, 2001 | 173 | 2001 |
| Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target CA Von Roemeling, LA Marlow, AB Pinkerton, A Crist, J Miller, HW Tun, ... The Journal of Clinical Endocrinology & Metabolism 100 (5), E697-E709, 2015 | 145 | 2015 |
| Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma HW Tun, PB Johnston, LM DeAngelis, PJ Atherton, LD Pederson, ... Blood, The Journal of the American Society of Hematology 132 (21), 2240-2248, 2018 | 128 | 2018 |
| The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma TE Witzig, C Reeder, JJ Han, B LaPlant, M Stenson, HW Tun, W Macon, ... Blood, The Journal of the American Society of Hematology 126 (3), 328-335, 2015 | 127 | 2015 |
| Long-term repair of T-cell synapse activity in a phase II trial of chemoimmunotherapy followed by lenalidomide consolidation in previously untreated chronic lymphocytic … TD Shanafelt, AG Ramsay, CS Zent, JF Leis, HW Tun, TG Call, B LaPlant, ... Blood, The Journal of the American Society of Hematology 121 (20), 4137-4141, 2013 | 105 | 2013 |
| Pomalidomide shows significant therapeutic activity against CNS lymphoma with a major impact on the tumor microenvironment in murine models Z Li, Y Qiu, D Personett, P Huang, B Edenfield, J Katz, D Babusis, Y Tang, ... PloS one 8 (8), e71754, 2013 | 104 | 2013 |
| Lipid rafts play an important role in Aβ biogenesis by regulating the β-secretase pathway H Tun, L Marlow, I Pinnix, R Kinsey, K Sambamurti Journal of Molecular Neuroscience 19, 31-35, 2002 | 101 | 2002 |
| Introduction of novel agents in the treatment of primary CNS lymphoma C Grommes, L Nayak, HW Tun, TT Batchelor Neuro-oncology 21 (3), 306-313, 2019 | 98 | 2019 |
| Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies LA Marlow, CA von Roemeling, SJ Cooper, Y Zhang, SD Rohl, S Arora, ... Journal of cell science 125 (18), 4253-4263, 2012 | 81 | 2012 |
| S100A8 is a novel therapeutic target for anaplastic thyroid carcinoma AN Reeb, W Li, W Sewell, LA Marlow, HW Tun, RC Smallridge, ... The Journal of Clinical Endocrinology & Metabolism 100 (2), E232-E242, 2015 | 73 | 2015 |
| Defining the human kidney N‐glycome in normal and cancer tissues using MALDI imaging mass spectrometry RR Drake, C McDowell, C West, F David, TW Powers, T Nowling, ... Journal of Mass Spectrometry 55 (4), e4490, 2020 | 69 | 2020 |
| Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers SJ Cooper, CA Von Roemeling, KH Kang, LA Marlow, SK Grebe, ... Molecular cancer therapeutics 11 (10), 2105-2115, 2012 | 66 | 2012 |
| The physician–patient relationship and quality of life: Lessons from chronic lymphocytic leukemia TD Shanafelt, DA Bowen, C Venkat, SL Slager, CS Zent, NE Kay, ... Leukemia research 33 (2), 263-270, 2009 | 63 | 2009 |
| Loss of type III transforming growth factor-β receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma SJ Cooper, H Zou, SN LeGrand, LA Marlow, CA Von Roemeling, ... Oncogene 29 (20), 2905-2915, 2010 | 62 | 2010 |
| Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma? O Saifi, WG Breen, SC Lester, WG Rule, B Stish, A Rosenthal, J Munoz, ... Radiotherapy and Oncology 166, 171-179, 2022 | 51 | 2022 |
